Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

Furst, D E; Breedveld, F C; Kalden, Joachim R.; Smolen, J S; Burmester, G. R.; Sieper, J.; Emery, Paul; Keystone, E.; Schiff, M.H.; Mease, Philip J; Riel, P. L. C. M. van; Fleischmann, Roy; Weisman, M H; Weinblatt, Michael E.

doi:10.1136/ard.2007.081430

Cited by 131 publications

(126 citation statements)

References 136 publications

(290 reference statements)

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…The clinical manifestations of PsA in this large study cohort are consistent with the typical pattern of PsA symptoms reported in the literature, and the patient characteristics are representative of those considered eligible for anti-TNF therapy 1 2 13 14. After 12 weeks of adalimumab therapy, 74%, 51% and 32% of the patients experienced ACR20, 50 and 70 responses, respectively.…”

Section: Discussionsupporting

confidence: 83%

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions

et al. 2009

View full text Add to dashboard Cite

Objectives:To evaluate the effectiveness of adalimumab in patients with psoriatic arthritis (PsA) and identify predictors of good clinical response for joint and skin lesions.Methods:Patients received adalimumab 40 mg every other week in addition to standard therapy in this prospective, 12-week, open-label, uncontrolled study. Four definitions of good clinical response were used: ⩾50% improvement in American College of Rheumatology response criteria (ACR50), good response according to European League Against Rheumatism (EULAR) guidelines, a ⩾3-grade improvement in Physician Global Assessment of psoriasis (PGA) and a ⩾50% improvement in the Nail Psoriasis Severity Index (NAPSI). Response predictors were determined by logistic regression with backward elimination (selection level was 5%).Results:Of 442 patients, 94% completed 12 weeks of treatment. At week 12, 74%, 51% and 32% of the patients had achieved ACR20, 50 and 70, respectively; 87% and 61% experienced moderate and good responses according to EULAR criteria, respectively. The percentage of patients with PGA results of “clear/almost clear” increased from 34% (baseline) to 68%. The mean NAPSI score was reduced by 44%. No new safety signals were detected. A lower Health Assessment Questionnaire Disability Index (HAQ-DI) score, greater pain assessment, male sex and absence of systemic glucocorticoid therapy were strongly associated with achievement of ACR50 and good response according to EULAR criteria. In addition, greater C-reactive protein concentration and polyarthritis predicted ACR50, and non-involvement of large joints predicted a good response according to EULAR criteria.Conclusions:Adalimumab was effective in patients with PsA. Lower impairment of physical function, greater pain, male sex and no systemic treatment with glucocorticoids were factors that increased the chance of achieving a good clinical response.

show abstract

Section: Discussionsupporting

confidence: 83%

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions

et al. 2009

View full text Add to dashboard Cite

show abstract

“…All patients fulfilled the American College of Rheumatology 1987 revised criteria for RA,14 and had active disease, indicated by a disease activity score in 28 joints (DAS28) of ≥3.2 despite earlier treatment with two disease-modifying antirheumatic drugs (DMARDs), including methotrexate (MTX), at a dosage of 25 mg weekly or at the maximal tolerable dosage, according to the Dutch consensus statement on the initiation and continuation of TNF blocking treatment in RA 15. Patients were treated with either adalimumab and concomitant DMARD treatment or adalimumab monotherapy.…”

Section: Methodsmentioning

confidence: 99%

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

Bartelds¹,

Wijbrandts

Nurmohamed

et al. 2009

Annals of the Rheumatic Diseases

200

143

View full text Add to dashboard Cite

Switchers with anti-infliximab antibodies more often develop antibodies against adalimumab than anti-TNF naive patients. Response to adalimumab was limited in switchers without anti-infliximab antibodies, which raises the question whether a second anti-TNF treatment should be offered to patients with RA for whom an initial treatment with an anti-TNF blocker fails, in the absence of anti-biological antibodies.

show abstract

“…The American College of Rheumatology (ACR) recommends re-evaluation of patients who have not achieved clinical benefit within 12 weeks of initiating anti-TNF therapy 3. Given the short period of time in which physicians are expected to make treatment decisions, it has become increasingly important to identify features in individual patients that may assist in decisions to continue or discontinue a treatment regimen.…”

mentioning

confidence: 99%

Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial

et al. 2011

View full text Add to dashboard Cite

Objective To derive and validate decision trees to categorize rheumatoid arthritis (RA) patients 12 weeks after starting etanercept with or without methotrexate into three groups: patients predicted to achieve low disease activity (LDA) at 1 year; patients predicted to not achieve LDA at 1 year; and patients who needed additional time on therapy to be categorized. Methods Data from RA patients enrolled in TEMPO were analyzed. Classification and Regression Trees were used to develop and validate decision-tree models with week 12 and earlier assessments that predicted long-term LDA. LDA, defined as DAS28 ≤ 3.2 or Clinical Disease Activity Index (CDAI) ≤ 10.0, was measured at 52 or 48 weeks. Demographics, laboratory data, and clinical data at baseline and through week 12 were analyzed as predictors of response. Results Thirty-nine percent (67/172) of patients receiving etanercept and 60% (115/193) of patients receiving etanercept plus methotrexate achieved LDA at week 52. For patients receiving etanercept, 53% were predicted to have LDA, 39% were predicted to not have LDA, and 8% could not be categorized using DAS28 criteria at week 12. For patients receiving etanercept plus methotrexate, 63% were predicted to have LDA, 25% were predicted to not have LDA, and 12% could not be categorized. Conclusion Most (80%–90%) patients in TEMPO initiating etanercept with or without methotrexate could be predicted within 12 weeks of starting therapy as likely to have LDA or not at week 52. However, approximately 10%–20% of patients needed additional time on therapy to decide whether to continue treatment.

show abstract

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

Cited by 131 publications

References 136 publications

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial

Contact Info

Product

Resources

About